Zoetis Inc. $ZTS Shares Bought by Kathmere Capital Management LLC

Key Points

• Kathmere Capital Management LLC increased its stake in Zoetis Inc. by 58.7%, owning 8,252 shares valued at approximately $1.287 million at the end of the last reporting period.
• Analyst ratings for Zoetis are mixed, with five analysts giving it a "Buy" rating and four a "Hold," leading to an overall consensus rating of "Moderate Buy" with an average target price of $200.88.
• Zoetis reported a quarterly EPS of $1.76, exceeding estimates, with revenue of $2.46 billion, highlighting a year-over-year revenue growth of 4.2%.

Kathmere Capital Management LLC raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 58.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 8,252 shares of the company's stock after purchasing an additional 3,051 shares during the period. Kathmere Capital Management LLC's holdings in Zoetis were worth $1,287,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Nova Wealth Management Inc. acquired a new stake in shares of Zoetis during the first quarter valued at $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis during the first quarter valued at $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis during the first quarter valued at $29,000. Cornerstone Planning Group LLC boosted its stake in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after acquiring an additional 120 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of analyst reports. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Argus reiterated a "buy" rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler raised their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Stock Up 1.7%

Shares of NYSE:ZTS opened at $143.52 on Friday. The stock's 50-day moving average price is $150.35 and its two-hundred day moving average price is $155.72. The firm has a market cap of $63.61 billion, a price-to-earnings ratio of 24.70, a PEG ratio of 2.27 and a beta of 0.89. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $197.51.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period last year, the business posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.